The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 1.23
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sitesa
Both Sexes by Race/Ethnicity
| Race/Ethnicity | Primary Site | Age-Adjusted Rateb, 2013-2017 |
Trend (APC)c, 2008-2017 |
|---|---|---|---|
| All Races | All Sites | 442.4 | -1.1* |
| Breast | 68.9 | 0.0 | |
| Lung and Bronchus | 54.2 | -2.2* | |
| Prostatef | 50.2 | -4.3* | |
| Colon and Rectum | 38.2 | -2.3* | |
| Melanoma of the Skin | 22.7 | 1.2* | |
| Urinary Bladder | 20.0 | -1.4* | |
| Non-Hodgkin Lymphoma | 19.6 | -0.8* | |
| Kidney and Renal Pelvis | 16.3 | 0.4* | |
| Thyroid | 15.7 | 1.0 | |
| Corpus and Uterus, NOSf | 14.8 | 0.9* | |
| Leukemia | 14.1 | -0.3 | |
| Pancreas | 13.1 | 0.5* | |
| Oral Cavity and Pharynx | 11.4 | 0.5* | |
| Liver & IBDg | 9.0 | 1.4* | |
| Stomach | 7.3 | -0.8* | |
| White | All Sites | 452.1 | -1.1* |
| Breast | 69.5 | -0.2 | |
| Lung and Bronchus | 56.0 | -2.2* | |
| Prostatef | 47.3 | -4.8* | |
| Colon and Rectum | 37.8 | -2.2* | |
| Melanoma of the Skin | 27.2 | 1.3* | |
| Urinary Bladder | 22.0 | -1.4* | |
| Non-Hodgkin Lymphoma | 20.6 | -0.8* | |
| Kidney and Renal Pelvis | 16.8 | 0.5* | |
| Thyroid | 16.4 | 0.7 | |
| Leukemia | 15.0 | -0.4 | |
| Corpus and Uterus, NOSf | 14.9 | 0.6* | |
| Pancreas | 13.1 | 0.5* | |
| Oral Cavity and Pharynx | 12.0 | 0.6* | |
| Liver & IBDg | 8.1 | 1.9* | |
| Brain and ONSg | 7.1 | -0.7* | |
| Black | All Sites | 440.4 | -1.6* |
| Prostatef | 74.4 | -4.2* | |
| Breast | 71.3 | 0.2 | |
| Lung and Bronchus | 54.8 | -2.7* | |
| Colon and Rectum | 43.6 | -3.0* | |
| Kidney and Renal Pelvis | 17.5 | 0.1 | |
| Corpus and Uterus, NOSf | 15.9 | 1.5* | |
| Pancreas | 15.3 | 0.1 | |
| Non-Hodgkin Lymphoma | 14.7 | -0.5* | |
| Myeloma | 13.8 | 0.3 | |
| Urinary Bladder | 11.8 | -0.8* | |
| Leukemia | 10.8 | 0.3 | |
| Liver & IBDg | 10.7 | 0.7 | |
| Stomach | 10.1 | -2.1* | |
| Thyroid | 9.5 | 1.3 | |
| Oral Cavity and Pharynx | 8.5 | -1.2* | |
| Asian/ Pacific Islander |
All Sites | 302.1 | -0.8* |
| Breast | 56.3 | 1.2* | |
| Lung and Bronchus | 36.2 | -1.1* | |
| Colon and Rectum | 31.8 | -2.5* | |
| Prostatef | 25.1 | -4.9* | |
| Thyroid | 15.8 | 1.2* | |
| Non-Hodgkin Lymphoma | 13.5 | -0.5 | |
| Liver & IBDg | 12.9 | -2.2* | |
| Corpus and Uterus, NOSf | 11.8 | 1.9* | |
| Stomach | 10.6 | -2.6* | |
| Pancreas | 10.0 | 0.3 | |
| Urinary Bladder | 8.9 | -0.9* | |
| Kidney and Renal Pelvis | 8.8 | 0.8 | |
| Oral Cavity and Pharynx | 8.5 | 0.4 | |
| Leukemia | 8.0 | -0.4 | |
| Ovaryf h | 5.1 | -1.0 | |
| American Indian/ Alaska Natived |
All Sites | 310.1 | -1.0* |
| Breast | 42.7 | -0.5 | |
| Colon and Rectum | 39.0 | -1.1 | |
| Lung and Bronchus | 38.1 | -1.8* | |
| Prostatef | 24.3 | -5.4* | |
| Kidney and Renal Pelvis | 17.9 | -0.3 | |
| Liver & IBDg | 14.9 | 1.2 | |
| Non-Hodgkin Lymphoma | 10.9 | -3.3* | |
| Corpus and Uterus, NOSf | 10.6 | -0.8 | |
| Pancreas | 10.0 | 1.1 | |
| Urinary Bladder | 9.6 | 1.6 | |
| Thyroid | 9.3 | 2.3* | |
| Stomach | 8.4 | -1.3 | |
| Oral Cavity and Pharynx | 8.1 | -0.4 | |
| Leukemia | 8.1 | -0.8 | |
| Myeloma | 5.7 | 2.9 | |
| Hispanice | All Sites | 348.4 | -1.1* |
| Breast | 53.2 | 0.4 | |
| Prostatef | 40.7 | -5.5* | |
| Colon and Rectum | 33.7 | -1.8* | |
| Lung and Bronchus | 29.0 | -2.2* | |
| Non-Hodgkin Lymphoma | 18.1 | -0.4* | |
| Kidney and Renal Pelvis | 16.1 | 1.0* | |
| Thyroid | 14.2 | 2.3* | |
| Liver & IBDg | 13.7 | 0.6 | |
| Corpus and Uterus, NOSf | 13.1 | 2.1* | |
| Pancreas | 11.6 | 0.1 | |
| Urinary Bladder | 11.0 | -1.5* | |
| Leukemia | 10.9 | -0.6 | |
| Stomach | 10.5 | -1.2* | |
| Oral Cavity and Pharynx | 6.8 | -1.2* | |
| Myeloma | 6.8 | 0.2 |
Footnotes:
Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
a Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.
b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
c The APC is the Annual Percent Change over the time interval. Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
d Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.
e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
f The rates for sex-specific cancer sites are calculated using the population for both sexes combined.
g IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.
h Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.
* The APC is significantly different from zero (p<.05).
- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.